[go: up one dir, main page]

MX9702473A - Composiciones farmaceuticas parenterales que contienen gf120918a. - Google Patents

Composiciones farmaceuticas parenterales que contienen gf120918a.

Info

Publication number
MX9702473A
MX9702473A MX9702473A MX9702473A MX9702473A MX 9702473 A MX9702473 A MX 9702473A MX 9702473 A MX9702473 A MX 9702473A MX 9702473 A MX9702473 A MX 9702473A MX 9702473 A MX9702473 A MX 9702473A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
gf120918a
compositions containing
parenteral pharmaceutical
safe
Prior art date
Application number
MX9702473A
Other languages
English (en)
Other versions
MXPA97002473A (es
Inventor
Wei Qin Tong
Mickey Lee Wells
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of MX9702473A publication Critical patent/MX9702473A/es
Publication of MXPA97002473A publication Critical patent/MXPA97002473A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a composiciones farmacéuticas que previenen o minimizan la precipitacion después de la inyeccion o infusion, que comprenden: a) una cantidad segura y terapéuticamente efectiva de N-[4-[2-1.2.3.4-tetrahidro-6.7-dimetoxi-2-isoquino linil)-etil]-fenil)-9.10-dohidro-5-metoxi-9-oxo-4- acridina carboxamida y sus sales y solvatos fisiologicamente aceptables; b) una cantidad segura y efectiva de un tensoactivo; c) un sistema regulador de pH; y d) un vehículo farmacéuticamente aceptable.
MXPA/A/1997/002473A 1994-10-05 1997-04-04 Composiciones farmaceuticas parenterales que contienen gf120918a MXPA97002473A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US318308 1981-11-05
US31830894A 1994-10-05 1994-10-05
USUS95/12952 1995-10-04
PCT/US1995/012952 WO1996011007A1 (en) 1994-10-05 1995-10-04 Parenteral pharmaceutical compositions containing gf120918a

Publications (2)

Publication Number Publication Date
MX9702473A true MX9702473A (es) 1997-07-31
MXPA97002473A MXPA97002473A (es) 1997-12-01

Family

ID=

Also Published As

Publication number Publication date
HUT77883A (hu) 1998-09-28
CZ104197A3 (en) 1997-09-17
AU702519B2 (en) 1999-02-25
BR9509251A (pt) 1997-10-21
KR970705997A (ko) 1997-11-03
CA2201628A1 (en) 1996-04-18
AU3891395A (en) 1996-05-02
PL319511A1 (en) 1997-08-18
NZ295546A (en) 1999-01-28
EP0784474A2 (en) 1997-07-23
RU2157687C2 (ru) 2000-10-20
WO1996011007A1 (en) 1996-04-18
JPH10507177A (ja) 1998-07-14

Similar Documents

Publication Publication Date Title
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
MX9805539A (es) Uso de un agonista del receptor activado proliferador de peroxisomas alfa y del receptor activado proliferador de peroxisomas gamma, para el tratamiento del sindrome x.
GR3029396T3 (en) Cosolvent parenteral formulation of tirilazad
AU4534593A (en) Compositions and methods for enhanced drug delivery
HUT75089A (en) Compositions containing hyaluronic acid or it's derivatives and pharmaceutical active agent
HUT57202A (en) Process for producing new pharmaceutically active 5-fluoro-2-///4-/cyclopropyl-methoxy/-2-pyridinyl/-methyl-sulfonyl/-1h-benzimidazol and pharmaceutical compositions containing them
IL124459A0 (en) Antagonists of gonadotropin releasing hormone
MX9804850A (es) Antagonistas de hormona liberadora de gonadotropina.
ZA964735B (en) Compositions and methods for topical administration of pharmaceutically active agents
KR100206481B1 (en) Galenic form for ocular administration and process for the preparation of same
ZA962248B (en) Nanususpensions for intravenous administration
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
MX9802150A (es) Inhibicion del factor alfa de necrosis tumoral.
IL126178A0 (en) Methods for stabilizing compositions containing taxol and pharmaceutical compositions containing taxol prepared
NZ218615A (en) S-(-)-1-propyl-2',6'-pipecoloxylidide hydrochloride monohydrate and local anesthesia compositions
IL103294A0 (en) Pharmaceutical compositions for preventing tissue damage associated with decreased blood flow
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
GB2245831B (en) Drug delivery system for administering growth factors
NZ230356A (en) 2',3'-dideoxy-5-ethynyl-3'-fluorouridine: preparatory processes and pharmaceutical compositions
MX9702473A (es) Composiciones farmaceuticas parenterales que contienen gf120918a.
IL112110A0 (en) Octahydro-1h-isoindoles and pharmaceutical compositions containing them
GB9321104D0 (en) Parenteral administration of altrenogest and compositions therefor
ITMI911023A0 (it) Procedimento ed impianto per l'alimentazione di filatoi
AU2403592A (en) 2-aza-2-desamino analogues of 5,8-dideazafolic acid
MX9701529A (es) Uso de (e)-1-[4'-(2-alquilaminoetoxi)fenil]-1-(3'-hidroxifenil)-2-f enilbut-1-enos para inhibir trastornos patologicos.